☆ 4.6 Article

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial

ECLINICALMEDICINE (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study (Publication with Expression of Concern. See vol. 401, pg. 90, 2023)

Chaolin Huang et al.

Summary: This study aimed to investigate the long-term health consequences of discharged COVID-19 patients and associated risk factors, particularly disease severity. Patients with more severe illness during hospitalization showed more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, highlighting the need for targeted interventions for long-term recovery.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Raches Ella et al.

Summary: The BBV152 vaccine demonstrated tolerable safety outcomes and enhanced immune responses in this clinical trial, leading to selection of both Algel-IMDG formulations for phase 2 immunogenicity trials. Further efficacy trials are warranted to validate the vaccine's effectiveness.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Jordan R. Barrett et al.

Summary: The study demonstrates that a booster dose of ChAdOx1 nCoV-19 is safer and better tolerated than priming doses. The booster dose significantly enhances anti-spike neutralizing antibody titers and other functional antibody responses. These data support the two-dose vaccine regime currently being evaluated in phase 3 clinical trials.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Peter Richmond et al.

Summary: A study in Australia evaluated the dose-finding and adjuvant justification of the SCB-2019 vaccine against SARS-CoV-2. The vaccine, which contains a stabilised trimeric form of the spike protein (S-Trimer) combined with AS03 or CpG/Alum adjuvants, elicited robust humoral and cellular immune responses in both younger and older adults.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang et al.

Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 dose-ranging study ,

Paul A. Goepfert et al.

Summary: The CoV2 preS dTM vaccine is being developed against SARS-CoV-2 and the interim results of the first-in-human study show lower than expected immune responses, especially in older age groups, and high reactogenicity after the second dose. Further development of the AS03-adjuvanted candidate vaccine will focus on identifying the optimal antigen formulation and dose.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Keith J. Chappell et al.

Summary: The study evaluated the safety and immunogenicity of a novel COVID-19 vaccine, showing promising results in both aspects. Adverse reactions were minimal, and the vaccine elicited antigen-specific responses regardless of the dosage.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Letter Medicine, General & Internal

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Guo-Lin Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

S. A. Madhi et al.

Summary: The ChAdOx1 nCoV-19 vaccine did not provide significant protection against mild-to-moderate Covid-19 caused by the B.1.351 variant, with an efficacy of 10.4%. The incidence of serious adverse events was balanced between the vaccine and placebo groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Nicole Doria-Rose et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19

Jun Wu et al.

Summary: The study quantified IgM and IgG antibodies recognizing SARS-CoV-2 in 349 symptomatic COVID-19 patients over 6 months, showing that IgM levels dropped after 3 months while IgG responses contracted but remained high at 6 months.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Hong-Xing Pan et al.

Summary: This study reported the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. The vaccine demonstrated good tolerability and induced robust immune responses in both phase 1 and phase 2 trials.

CHINESE MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Clinical Characteristics of Coronavirus Disease 2019 in China

W. Guan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Rapid COVID-19 vaccine development

Barney S. Graham

SCIENCE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Letter Biotechnology & Applied Microbiology

Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures

Nikolai Eroshenko et al.

NATURE BIOTECHNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan et al.

FRONTIERS OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Maheshi N. Ramasamy et al.

LANCET (2020)

添加到收藏夹

Article Immunology

Low toxicity and high immunogenicity of an inactivated vaccine candidate against COVID-19 in different animal models

Ze-Jun Wang et al.

EMERGING MICROBES & INFECTIONS (2020)

添加到收藏夹

Article Immunology

Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Gemma E. Hartley et al.

SCIENCE IMMUNOLOGY (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.